<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Patients with a <z:hpo ids='HP_0001655'>patent foramen ovale</z:hpo> (<z:mp ids='MP_0004225'>PFO</z:mp>) and <z:e sem="disease" ids="C0238096" disease_type="Disease or Syndrome" abbrv="">paradoxical embolism</z:e> are at risk for recurrent <z:hpo ids='HP_0001907'>thromboembolic events</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>This study investigated the long-term risk of recurrent <z:hpo ids='HP_0001907'>thromboembolic events</z:hpo> in patients with <z:mp ids='MP_0004225'>PFO</z:mp> and <z:e sem="disease" ids="C0238096" disease_type="Disease or Syndrome" abbrv="">paradoxical embolism</z:e> after percutaneous <z:mp ids='MP_0004225'>PFO</z:mp> closure </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS AND RESULTS: Since 1994, a total of 80 patients with <z:mp ids='MP_0004225'>PFO</z:mp> and at least 1 paradoxical embolic event (<z:hpo ids='HP_0002326'>transient ischemic attack</z:hpo> [<z:hpo ids='HP_0002326'>TIA</z:hpo>], <z:hpo ids='HP_0001297'>cerebrovascular accident</z:hpo> [<z:chebi fb="4" ids="46274">CVA</z:chebi>], peripheral embolism) have undergone percutaneous <z:mp ids='MP_0004225'>PFO</z:mp> closure with 5 different devices </plain></SENT>
<SENT sid="3" pm="."><plain>There were 30 women and 50 men, with a mean age of 52+/-12 years </plain></SENT>
<SENT sid="4" pm="."><plain>Sixty patients had only a <z:mp ids='MP_0004225'>PFO</z:mp>, whereas 20 patients had both a <z:mp ids='MP_0004225'>PFO</z:mp> and an <z:hpo ids='HP_0011995'>atrial septal aneurysm</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>The implantation procedure was successful in 78 patients (98%) </plain></SENT>
<SENT sid="6" pm="."><plain>During 5 years of follow-up (mean, 1.6+/-1.4 years; range, 0.1 to 5.0 years), the actuarial annual risk to suffer a recurrent thromboembolic event was 2.5% for <z:hpo ids='HP_0002326'>TIA</z:hpo>, 0% for <z:chebi fb="4" ids="46274">CVA</z:chebi>, 0.9% for peripheral emboli, and 3.4% for the combined end point of <z:hpo ids='HP_0002326'>TIA</z:hpo>, <z:chebi fb="4" ids="46274">CVA</z:chebi>, or peripheral embolism </plain></SENT>
<SENT sid="7" pm="."><plain>A postprocedural shunt was a predictor of recurrent <z:e sem="disease" ids="C0238096" disease_type="Disease or Syndrome" abbrv="">paradoxical embolism</z:e> (RR, 4.2; 95% CI, 1.1 to 17.8; P=0.03) </plain></SENT>
<SENT sid="8" pm="."><plain>The risk for recurrent <z:hpo ids='HP_0001907'>thromboembolic events</z:hpo> in patients with both <z:hpo ids='HP_0011995'>atrial septal aneurysm</z:hpo> and <z:mp ids='MP_0004225'>PFO</z:mp> was not significantly increased compared with patients with only <z:mp ids='MP_0004225'>PFO</z:mp> (RR, 1.0; 95% CI, 0.2 to 4.7; P=0.95) </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: Percutaneous <z:mp ids='MP_0004225'>PFO</z:mp> closure appears to be a promising technique in the prevention of recurrent systemic <z:hpo ids='HP_0001907'>thromboembolism</z:hpo> in patients with a <z:mp ids='MP_0004225'>PFO</z:mp> after a first event </plain></SENT>
<SENT sid="10" pm="."><plain>Prospective studies comparing percutaneous <z:mp ids='MP_0004225'>PFO</z:mp> closure with antithrombotic medications or surgery must define its therapeutic value </plain></SENT>
</text></document>